Systemic sclerosis
MONDO:0005100A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.
Also known as: Scleroderma, PSS (progressive systemic sclerosis), SSc, SSc, diffuse sclerosis, Scleroderma (& [systemic sclerosis]), Scleroderma, diffuse, Scleroderma, systemic, Systemic Scleroderma
318 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a painless microneedle pad ease Raynaud's in scleroderma?
Disease control Not yet recruitingThis Phase 3 trial is testing whether a microneedle pad delivering botulinum toxin A can improve symptoms of Raynaud's phenomenon and digital ulcers in people with systemic sclerosis. The study compares the microneedle treatment to a placebo, measuring changes in finger temperatu…
Phase: PHASE3 • Sponsor: Khon Kaen University • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Could a single injection reprogram immune cells to tame lupus and scleroderma?
Disease control Not yet recruitingThis early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A drug after transplant may stop scleroderma from coming back
Disease control Not yet recruitingThis pilot trial tests whether giving the immunosuppressant drug mycophenolate mofetil (MMF) for six months after a stem cell transplant can prevent systemic sclerosis from relapsing. Six adults with scleroderma who are undergoing a stem cell transplant will take MMF starting 90 …
Phase: PHASE2 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new pill ease the hardening skin of systemic sclerosis?
Disease control Not yet recruitingThis phase II trial is testing an experimental tablet called TollB-001 in adults with systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. The study aims to see whether the drug can improve skin symptoms and overall well-being …
Phase: PHASE2 • Sponsor: Toll Biotech Co. Ltd. (Beijing) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Not yet recruitingThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can engineered immune cells tame stubborn autoimmune diseases?
Disease control Not yet recruitingThis phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
Disease control Not yet recruitingThis phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Off-the-Shelf CAR-Ts take on lupus and more
Disease control Not yet recruitingThis early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug HBM7020 tested in humans for first time against autoimmune diseases
Disease control Not yet recruitingThis first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells aim to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose di…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could CAR-T cells tame autoimmune diseases? early safety trial launches
Disease control Not yet recruitingThis early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stem cells aim to calm the immune attack in scleroderma
Disease control Not yet recruitingThis early-stage trial tests a stem cell injection (HS_SW01) in 21 adults with systemic sclerosis, a disease where the immune system attacks the body, causing skin hardening and organ damage. The main goal is to see if the treatment is safe and tolerable. Researchers will also ch…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Huishan Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody drug firsekibart tested for scleroderma skin thickening
Disease control Not yet recruitingThis early-stage trial will test a new drug called firsekibart in 30 people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Firsekibart is an antibody that blocks a protein involved in inflammation. The study will measure changes in …
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Immune retraining: could CAR-Treg cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental cell infusion aims to tame childhood autoimmune diseases
Disease control Not yet recruitingThis early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will…
Phase: PHASE1 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingThis early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem Cell-Derived 'Living Drug' takes aim at tough autoimmune conditions
Disease control Not yet recruitingThis early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safe…
Phase: EARLY_PHASE1 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Not yet recruitingThis early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cizutamig tested for rare hardening skin disease
Disease control Not yet recruitingThis early-phase trial will test the safety and tolerability of a new drug called cizutamig in 10 adults with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. Participants must have moderate to severe skin involvement and have not responded well…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:20 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
New drug GB261 tested for rare Hardening-Skin disease
Disease control Not yet recruitingThis early-phase trial tests a new drug called GB261 in 10 people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The main goal is to check safety and how the body handles the drug. Researchers will also look for early signs that it might …
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC
-
New study aims to catch silent lung threat in scleroderma
Diagnosis Not yet recruitingThis study will screen 35 adults with scleroderma for pulmonary hypertension using echocardiography. The goal is to see how often this serious lung condition occurs in these patients. The study is not yet recruiting.
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
Symptom relief Not yet recruitingThis study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose th…
Phase: PHASE2 • Sponsor: Liquidia Technologies, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Finger injections aim to loosen stiff hands in scleroderma
Symptom relief Not yet recruitingThis early-phase trial investigates whether monthly injections of hyaluronidase into the fingers can improve stiffness and hand function in people with systemic sclerosis who have sclerodactyly (tight, thickened skin on the fingers). The study enrolls 10 adults aged 18 to 60 and …
Phase: EARLY_PHASE1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Fat stem cells injected into face could ease scleroderma mouth stiffness
Symptom relief Not yet recruitingThis study tests whether injections of stem cells from donated fat tissue can help loosen mouth fibrosis in people with systemic scleroderma. Fifty adults with limited mouth opening will receive either stem cell or placebo injections around the mouth and be followed for 24 weeks.…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Immune clues in the blood may foretell heart trouble
Knowledge-focused Not yet recruitingThis study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Blood particles may reveal hidden clues to scleroderma complications
Knowledge-focused Not yet recruitingThis study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see …
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Scientists build lab models of scleroderma from Patients' blood cells
Knowledge-focused Not yet recruitingThis study aims to create stem cell lines from blood samples of 16 people: 4 with severe scleroderma, 4 with mild scleroderma, and 8 of their healthy relatives. These stem cells will be turned into various tissue types (like heart, skin, and immune cells) in the lab to study how …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
Knowledge-focused Not yet recruitingThis study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood markers may spot Kids' lung disease earlier
Knowledge-focused Not yet recruitingThis study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Simple blood test may predict lung damage in autoimmune diseases
Knowledge-focused Not yet recruitingThis study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis and systemic sclerosis, as well as healthy volunteers, and compare them with standard tests and lung functi…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scleroderma patients to decide: infographic vs. plain language for research results
Knowledge-focused Not yet recruitingThis study aims to find the best way to share research results with people who have scleroderma, a rare autoimmune disease. About 128 participants will be randomly assigned to receive either an infographic or a plain-language summary of a study. They will then rate how complete, …
Phase: NA • Sponsor: Lady Davis Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Scientists hunt for rogue immune cells in autoimmune diseases
Knowledge-focused Not yet recruitingThis study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Simple blood test may spot heart risk in scleroderma patients
Knowledge-focused Not yet recruitingThis study looks at whether a substance in the blood called catestatin is linked to heart and blood vessel problems in people with systemic sclerosis (scleroderma). Researchers will measure catestatin levels in 70 patients and compare them to healthy people. The goal is to see if…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New blood test could spot autoimmune diseases earlier
Knowledge-focused Not yet recruitingThis study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Scleroderma Patients' sleep troubles under the microscope
Knowledge-focused Not yet recruitingThis study will use an overnight sleep test (polysomnography) to measure breathing problems during sleep in 30 adults with systemic sclerosis (scleroderma). The goal is to find out how common sleep-disordered breathing is in this group. No treatment is given—this is purely an obs…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:11 UTC
-
Can a simple ultrasound reveal hidden gut damage in scleroderma?
Knowledge-focused Not yet recruitingThis study will use Doppler ultrasound to measure blood flow in the gut arteries of 74 people with systemic sclerosis (scleroderma) and compare them to healthy volunteers. The goal is to see if changes in blood flow relate to digestive symptoms and other organ problems. This is a…
Sponsor: Esraa Moustafa Mohammed • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:33 UTC
-
New study aims to predict best treatments for rheumatoid diseases using AI and health data
Knowledge-focused Not yet recruitingThis study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person…
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:31 UTC